Robin A. van der Meulen is a partner in DiCello Levitt’s New York office, where she represents clients in complex antitrust litigation. Prior to joining DiCello Levitt, Robin was a partner in a nationally-recognized antitrust practice group, where she gained more than a decade of experience litigating a wide variety of antitrust matters, including price-fixing, monopolization, benchmark and commodities manipulation, pay-for-delay agreements, and other anticompetitive practices.
Robin was appointed co-lead class counsel for end-payor plaintiffs in the Bystolic Antitrust Litigation, a pay-for-delay case pending in the Southern District of New York. She is also leading Novartis and Par Antitrust Litigation, another pay-for-delay case seeking to recover millions of dollars in overcharges relating to the hypertension drug Exforge on behalf of end-payor plaintiffs. Robin also represents end-payor plaintiffs in the Generic Pharmaceuticals Pricing Antitrust Litigation, a massive case against some of the biggest drug companies in the world alleging price-fixing and anticompetitive conspiracies.
Robin was previously an associate at Willkie Farr & Gallagher LLP, where she practiced antitrust and commercial litigation. She also served as a judicial intern in the United States Bankruptcy Court for the Eastern District of New York for Judge Elizabeth S. Stong.
Euromoney’s Women in Business Law Awards selected Robin as a finalist for Antitrust and Competition Lawyer of the Year. The Legal 500 recommends Robin for excellence in the field of Antitrust Civil Litigation and Class Actions, describing her as “persistent, persuasive, and well-respected by peers and opponents alike” and naming her a “Next Generation Partner.” She has been recognized as “Up and Coming” by Chambers & Partners USA and as a “Future Star” by Benchmark Litigation. She has also been selected to Benchmark’s “40 & Under Hot List” as one of “the best and brightest law firm partners” and someone who is “ready to take the reins.” Additionally, Robin was recognized by The Best Lawyers in America® in the Antitrust Law category.
Robin is an active member of the antitrust bar. She is the secretary and a member of the Executive Committee of the Antitrust Law Section of the New York State Bar Association (NYSBA), and a member of NYSBA House of Delegates. Robin is also a Vice Chair of the Insurance and Financial Services Committee of the Antitrust Section of the American Bar Association (ABA). Robin was previously a Vice Chair of the Antitrust Section’s Health Care & Pharmaceutical Committee of the ABA and the Executive Editor of that Committee’s Antitrust Health Care Chronicle. From 2012 to 2021, Robin was an editor of the Health Care Antitrust Week-In-Review, a weekly publication that summarizes antitrust news in the health care industry.
Updated Sep 2023
